Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism

Philip D. Koblik, Gerald L Denardo, Harvey J. Berger

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This review describes the use of monoclonal antibodies (MoAbs) for immunoscintigraphic detection of thrombosis and thromboembolism. Two major groups of MoAbs have been tested: Antibodies directed against platelets and antibodies directed against fibrin. Several antiplatelet antibodies have been developed that are directed against either the platelet membrane glycoprotein complex, IIb/IIIa, which binds fibrinogen, or against two different proteins, alpha granule membrane protein GMP-140 and thrombospondin (TSP) that are expressed during platelet activation. Platelets labeled with radiactive antibody or antibody fragments have characteristics similar to platelets labeled in vitro with lipophilic complexes. Studies in animal models indicate that antiplatelet antibody and antiactivated platelet factor antibody imaging have a high sensitivity for clots <24 hours old and that images can be positive as early as one to two hours after antibody administration. A limited number of antiplatelet antibody studies have been performed in patients. This technique appears to yield accurate results provided that active platelet deposition is occurring at the time of the study. Several antifibrin MoAbs, specific for fibrin monomers, have been developed. Compared with antiplatelet antibodies, antifibrin antibodies and antibody fragments appear to be capable of detecting older experimental clots (up to five days old). Images in experimental thrombosis models are routinely positive within two hours of antibody administration. Recently reported clinical trials indicate a high sensitivity in all anatomic locations within the extremities whether or not patients were receiving heparin.

Original languageEnglish (US)
Pages (from-to)221-237
Number of pages17
JournalSeminars in Nuclear Medicine
Volume19
Issue number3
DOIs
StatePublished - 1989

Fingerprint

Thromboembolism
Thrombosis
Antibodies
Blood Platelets
Immunoglobulin Fragments
Monoclonal Antibodies
Platelet Membrane Glycoprotein IIb
Thrombospondins
Platelet Glycoprotein GPIIb-IIIa Complex
P-Selectin
Time and Motion Studies
Platelet Activation
Fibrin
Fibrinogen
Heparin
Membrane Proteins
Theoretical Models
Extremities
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. / Koblik, Philip D.; Denardo, Gerald L; Berger, Harvey J.

In: Seminars in Nuclear Medicine, Vol. 19, No. 3, 1989, p. 221-237.

Research output: Contribution to journalArticle

@article{d83a2bd9ff024232959a6b42ee3da9ce,
title = "Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism",
abstract = "This review describes the use of monoclonal antibodies (MoAbs) for immunoscintigraphic detection of thrombosis and thromboembolism. Two major groups of MoAbs have been tested: Antibodies directed against platelets and antibodies directed against fibrin. Several antiplatelet antibodies have been developed that are directed against either the platelet membrane glycoprotein complex, IIb/IIIa, which binds fibrinogen, or against two different proteins, alpha granule membrane protein GMP-140 and thrombospondin (TSP) that are expressed during platelet activation. Platelets labeled with radiactive antibody or antibody fragments have characteristics similar to platelets labeled in vitro with lipophilic complexes. Studies in animal models indicate that antiplatelet antibody and antiactivated platelet factor antibody imaging have a high sensitivity for clots <24 hours old and that images can be positive as early as one to two hours after antibody administration. A limited number of antiplatelet antibody studies have been performed in patients. This technique appears to yield accurate results provided that active platelet deposition is occurring at the time of the study. Several antifibrin MoAbs, specific for fibrin monomers, have been developed. Compared with antiplatelet antibodies, antifibrin antibodies and antibody fragments appear to be capable of detecting older experimental clots (up to five days old). Images in experimental thrombosis models are routinely positive within two hours of antibody administration. Recently reported clinical trials indicate a high sensitivity in all anatomic locations within the extremities whether or not patients were receiving heparin.",
author = "Koblik, {Philip D.} and Denardo, {Gerald L} and Berger, {Harvey J.}",
year = "1989",
doi = "10.1016/S0001-2998(89)80015-7",
language = "English (US)",
volume = "19",
pages = "221--237",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism

AU - Koblik, Philip D.

AU - Denardo, Gerald L

AU - Berger, Harvey J.

PY - 1989

Y1 - 1989

N2 - This review describes the use of monoclonal antibodies (MoAbs) for immunoscintigraphic detection of thrombosis and thromboembolism. Two major groups of MoAbs have been tested: Antibodies directed against platelets and antibodies directed against fibrin. Several antiplatelet antibodies have been developed that are directed against either the platelet membrane glycoprotein complex, IIb/IIIa, which binds fibrinogen, or against two different proteins, alpha granule membrane protein GMP-140 and thrombospondin (TSP) that are expressed during platelet activation. Platelets labeled with radiactive antibody or antibody fragments have characteristics similar to platelets labeled in vitro with lipophilic complexes. Studies in animal models indicate that antiplatelet antibody and antiactivated platelet factor antibody imaging have a high sensitivity for clots <24 hours old and that images can be positive as early as one to two hours after antibody administration. A limited number of antiplatelet antibody studies have been performed in patients. This technique appears to yield accurate results provided that active platelet deposition is occurring at the time of the study. Several antifibrin MoAbs, specific for fibrin monomers, have been developed. Compared with antiplatelet antibodies, antifibrin antibodies and antibody fragments appear to be capable of detecting older experimental clots (up to five days old). Images in experimental thrombosis models are routinely positive within two hours of antibody administration. Recently reported clinical trials indicate a high sensitivity in all anatomic locations within the extremities whether or not patients were receiving heparin.

AB - This review describes the use of monoclonal antibodies (MoAbs) for immunoscintigraphic detection of thrombosis and thromboembolism. Two major groups of MoAbs have been tested: Antibodies directed against platelets and antibodies directed against fibrin. Several antiplatelet antibodies have been developed that are directed against either the platelet membrane glycoprotein complex, IIb/IIIa, which binds fibrinogen, or against two different proteins, alpha granule membrane protein GMP-140 and thrombospondin (TSP) that are expressed during platelet activation. Platelets labeled with radiactive antibody or antibody fragments have characteristics similar to platelets labeled in vitro with lipophilic complexes. Studies in animal models indicate that antiplatelet antibody and antiactivated platelet factor antibody imaging have a high sensitivity for clots <24 hours old and that images can be positive as early as one to two hours after antibody administration. A limited number of antiplatelet antibody studies have been performed in patients. This technique appears to yield accurate results provided that active platelet deposition is occurring at the time of the study. Several antifibrin MoAbs, specific for fibrin monomers, have been developed. Compared with antiplatelet antibodies, antifibrin antibodies and antibody fragments appear to be capable of detecting older experimental clots (up to five days old). Images in experimental thrombosis models are routinely positive within two hours of antibody administration. Recently reported clinical trials indicate a high sensitivity in all anatomic locations within the extremities whether or not patients were receiving heparin.

UR - http://www.scopus.com/inward/record.url?scp=0024690889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024690889&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(89)80015-7

DO - 10.1016/S0001-2998(89)80015-7

M3 - Article

C2 - 2669130

AN - SCOPUS:0024690889

VL - 19

SP - 221

EP - 237

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -